Results 161 to 170 of about 5,613,091 (316)

Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study [PDF]

, 2019
Andrew K. Whittaker, Anna Christine Drachmann Kragh, Judith Hartleib‐Geschwindner, Muna Albayaty, Anna Backlund, Peter J. Greasley, Maria Heijer, Michael Kjær, Pablo Forte, Robert J. Unwin, Linda Wernevik, Hans Ericsson   +11 more
openalex   +1 more source

​Did a Non‐Medical Biosimilar Switching Policy Cause an Increase in Non‐Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis?

Arthritis Care &Research, EarlyView.
Objective This study aimed to evaluate the impact of a series of policies that mandated switching patients with inflammatory arthritis (IA) from an originator biologic to a biosimilar in British Columbia, Canada, on health care resource use and cost.
HaoHung Dang, Sandra Blitz, Nick Bansback, Michael Law, Mark Harrison   +4 more
wiley   +1 more source

Implementing an Interprofessional Simulation Program for Paediatric Patient Safety. [PDF]

Clin Teach
D'Arienzo D, Dandavino M, Matte AA, Welsh S, Rich C, Korah N.   +5 more
europepmc   +1 more source

<p>An Observational Study of Intraoperative Neuromonitoring as a Safety Mechanism in Placement of Percutaneous Dorsal Root Ganglion Stimulation and Spinal Cord Stimulation Systems</p>

, 2020
Jonathan M. Hagedorn, Timothy R. Deer, Steven Falowski, Abhishek Yadav, Ashley Comer, Zayd Al-Asadi, Alyson M. Engle   +6 more
openalex   +2 more sources

Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump [PDF]

, 2018
James Thrasher, Howard K. Surks, Irene Nowotny, Suzanne Pierre, Baerbel Rotthaeuser, Karin Wernicke‐Panten, Satish K. Garg   +6 more
openalex   +1 more source

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

New England Journal of Medicine, 2002
G. Demetri, M. von Mehren, C. Blanke, A. D. Van den Abbeele, B. Eisenberg, P. Roberts, M. Heinrich, D. Tuveson, S. Singer, M. Janicek, J. Fletcher, S. Silverman, S. Silberman, R. Capdeville, B. Kiese, B. Peng, S. Dimitrijević, B. Druker, C. Corless, C. Fletcher, H. Joensuu   +20 more
semanticscholar   +1 more source

Reduction in Renal Relapse and Preservation of Long‐Term Kidney Function After Lupus Low Disease Activity in Patients With Lupus Nephritis

Arthritis Care &Research, EarlyView.
Objective Lupus low disease activity state (LLDAS) is a validated treatment target in systemic lupus erythematosus (SLE), but limited studies have explored the role of LLDAS in lupus nephritis (LN). This study aims to investigate the frequency and predictors of LLDAS attainment and its benefit on LN relapse and renal function preservation in patients ...
Chak Kwan Cheung, Desmond Y. H. Yap, Ka Lai Lee, Philip H. Li, Iris Y. K. Tang, Chak Sing Lau, Shirley C. W. Chan   +6 more
wiley   +1 more source

The refinement of drug safety governance based on contradiction matrix. [PDF]

BMC Public Health
Yao Y, Yang F, Zhang W.
europepmc   +1 more source

Improvements in Health‐Related Quality of Life With Treat‐to‐Target Urate‐Lowering Therapy in Gout: A Post Hoc Analysis of a Randomized Multicenter Trial

Arthritis Care &Research, EarlyView.
Objective Although treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL ...
Austin Barry, Bryant R. England, Harlan Sayles, Lindsay N. Helget, Maria Androsenko, Hongsheng Wu, Kaleb Michaud, Bridget Kramer, Jeff A. Newcomb, Mary T. Brophy, Anne Davis‐Karim, Ryan Ferguson, Michael H. Pillinger, Tuhina Neogi, Paul M. Palevsky, James R. O'Dell, Ted R. Mikuls   +16 more
wiley   +1 more source

Does road safety cointegrate with socio-economic conditions in rich developing countries? [PDF]

PLoS One
Alfaki IA, Grivna M, El Sadig M.
europepmc   +1 more source